These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11457523)

  • 1. Cholecystokinin modulation of apomorphine- or amphetamine-induced stereotypy in rats: opposite effects.
    Tieppo CA; Felicio LF; Nasello AG
    Peptides; 2001 Aug; 22(8):1291-8. PubMed ID: 11457523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opposite modulation of apomorphine- or amphetamine-induced stereotypy by antagonists of CCK receptors.
    Tieppo CA; Ferreira FS; Sassatani AS; Felicio LF; Nasello AG
    Eur J Pharmacol; 2000 Jan; 387(2):189-96. PubMed ID: 10650159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of apomorphine-induced stereotyped behavior by cholecystokinin.
    Tieppo CA; Nasello AG; Felicio LF
    Prog Neuropsychopharmacol Biol Psychiatry; 1997 May; 21(4):683-95. PubMed ID: 9194149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of either cholecystokinin receptor subtype reduces while antagonists potentiate or sensitize a morphine-induced excitatory response.
    Felicio LF; Mazzini BK; Cacheiro RG; Cruz TN; Flório JC; Nasello AG
    Peptides; 2001 Aug; 22(8):1299-304. PubMed ID: 11457524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracerebroventricular administration of cholecystokinin reduces stereotypy in dopamine-supersensitive rats.
    Tieppo CA; Silva AM; Palermo-Neto J; Nasello AG; Felicio LF
    Braz J Med Biol Res; 1995 Mar; 28(3):351-4. PubMed ID: 8520531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsy.
    Cohen SL; Knight M; Tamminga CA; Chase TN
    Eur J Pharmacol; 1982 Sep; 83(3-4):213-22. PubMed ID: 6129145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice.
    Kovács GL; Szabó G; Penke B; Telegdy G
    Eur J Pharmacol; 1981 Jan; 69(3):313-9. PubMed ID: 6260512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sulfated cholecystokinin octapeptide and cholecystokinin tetrapeptide in rat behavior after blockade of nitric oxide synthase by L-NAME.
    Hoły Z; Wiśniewski K
    Rocz Akad Med Bialymst; 1998; 43():250-70. PubMed ID: 9972062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed D2/5-HT2 antagonism differentially affects apomorphine- and amphetamine-induced stereotyped behavior.
    Feldman DJ; Frank RA; Kehne JH; Flannery R; Brown D; Soni S; Byrd G; Shah S
    Pharmacol Biochem Behav; 1997 Oct; 58(2):565-72. PubMed ID: 9300620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cholecystokinin on apomorphine-induced changes of motility in rats.
    Katsuura G; Itoh S; Rehfeld JF
    Neuropharmacology; 1984 Jul; 23(7A):731-4. PubMed ID: 6089021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enkephalin prevents CCK-induced enhancement of amphetamine-induced locomotor stereotypy.
    Mueller K; Whiteside DA
    Brain Res; 1990 Apr; 513(1):119-24. PubMed ID: 2350675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystokinin [corrected] octapeptide modulates dopamine release in rat striatum.
    Rakovska A
    Neurosci Lett; 1995 Aug; 195(3):151-4. PubMed ID: 8584197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for dopaminomimetic effect of intrastriatally injected cholecystokinin octapeptide in mice.
    Worms P; Martinez J; Briet C; Castro B; Biziere K
    Eur J Pharmacol; 1986 Mar; 121(3):395-401. PubMed ID: 3699101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence.
    Crawley JN; Stivers JA; Blumstein LK; Paul SM
    J Neurosci; 1985 Aug; 5(8):1972-83. PubMed ID: 4040554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin.
    Altar CA; Boyar WC
    Brain Res; 1989 Apr; 483(2):321-6. PubMed ID: 2706523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum.
    Tanganelli S; Li XM; Ferraro L; Von Euler G; O'Connor WT; Bianchi C; Beani L; Fuxe K
    Eur J Pharmacol; 1993 Jan; 230(2):159-66. PubMed ID: 8422898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of naloxone and morphine on dopamine agonist-induced stereotypy in rats and guinea pigs.
    Feigenbaum J; Yanai J; Moon B; Klawans H
    Neuropharmacology; 1983 Dec; 22(12A):1369-76. PubMed ID: 6686653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Startle and sensorimotor gating in rats lacking CCK-A receptors.
    Feifel D; Priebe K; Shilling PD
    Neuropsychopharmacology; 2001 Jun; 24(6):663-70. PubMed ID: 11331146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal by cholecystokinin of apomorphine-induced inhibition of dopamine release in the nucleus accumbens of the rat.
    Blaha CD; Phillips AG; Lane RF
    Regul Pept; 1987 Jun; 17(6):301-10. PubMed ID: 3602473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.